🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Zoetis Inc. ZTS SPXR3KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.zoetis.com
Company Profile ↓
$75.81
-49.31% 1Y
Mkt Cap$31.33B
P/E12.47
P/B9.27
Div. Yield2.74%
52W High$153.81
52W Low$71.36
Book Value$7.84
EPS (TTM)$6.08

Company Overview

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 80.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 27.2%.

Consistent Profit Growth

Net profit has compounded at 18.6% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 12.5, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 27.7%.

Dividend Income

Offers a dividend yield of 2.74%.

Recent Developments

  • Dec 2025 Revenue of $9.47B (+2.3% YoY); net profit $2.67B.
  • Trailing 12 Months Year-on-year growth — revenue +0.3%, earnings +2.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.9%, profit CAGR 18.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.92%
1 Year:0.30%

Compounded Profit Growth

5 Years:18.61%
1 Year:2.50%

Stock Price Performance

1 Year:-49.31%
6 Months:-36.86%
3 Months:-3.90%
1 Month:-1.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 5% of range
$71.36 $153.81
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)48.92 · Neutral
Price Performance
1M-1.89%
3M-3.90%
6M-36.86%
1Y-49.31%
Valuation vs Sector

P/E of 12.47 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 80.2%.
  • Healthy ROCE of 27.2%.
  • Excellent profit margin of 27.7%.
  • Profit CAGR of 18.6% over 5 years.
  • Attractive dividend yield of 2.74%.
  • Generates positive free cash flow.

CONS

  • Trading 50.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
12.47
Industry PE
25.17
Forward P/E
10.95
PEG Ratio
1.85
Book Value
$7.84
Price to Book
9.27
P/S
3.15
EV/EBITDA
9.07
Dividend Yield
2.74%

Growth (CAGR)

Revenue 5Y
5.92%
Profit 5Y
18.61%
Revenue (YoY)
0.30%
Earnings (YoY)
2.50%

Profitability & Returns

ROCE
27.18%
ROE
80.25%
ROA
17.28%
Profit Margin
27.68%
Op Margin
40.48%
Gross Margin
71.73%
EPS (Latest Qtr)
$1.65
EPS (TTM)
$6.08

Balance Sheet & Liquidity

Debt/Equity
2.86
Quick Ratio
1.94
Current Ratio
3.03
Debt
$9.24B
Total Assets
$15.08B
Current Assets
$6.47B
Working Capital
$4.53B

Ownership

Promoter Holding
0.16%
Chg in Prom Hold
0.01%
FII / Inst Holding
100.19%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
$31.33B
Total Revenue (TTM)
$9.53B
EBITDA
$4.07B
Free Cash Flow
$2.28B
Operating Cash Flow
$2.90B
Shares Outstanding
413.22M
Gross Margin
71.73%
Payout Ratio
33.88%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ZTS Zoetis Inc. SPXR3KPHARMA 75.81 12.47 $31.33B 2.74% 27.18% 80.25% 5.92% 18.61%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Apr 2016Jul 2016Oct 2016Dec 2016Apr 2017Jul 2017Oct 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------1.23B1.27B1.35B1.46B1.37B1.42B1.48B1.56B1.46B1.55B1.58B1.67B1.53B1.55B1.79B1.87B1.95B1.99B1.99B2.05B2.00B2.00B2.18B2.15B2.19B2.36B2.39B-2.20B2.46B2.40B2.39B2.26B2.47B
Cost of Revenue ----------------------------------618.00M649.00M683.00M712.00M641.00M-
Gross Profit ----------------------------------1.58B1.81B1.72B1.68B1.62B-
Operating Expenses ----------------------------------768.00M822.00M781.00M849.00M799.00M-
Operating Income ----------------------------------812.00M989.00M936.00M826.00M822.00M-
EBITDA ----------------------------------946.00M1.08B1.07B939.00M939.00M-
Interest Expense ----------------------------------54.00M53.00M58.00M57.00M62.00M-
Pretax Income ----------------------------------773.00M902.00M887.00M761.00M758.00M-
Tax Provision ----------------------------------171.00M184.00M166.00M158.00M157.00M-
Net Income 189.00M22.00M204.00M224.00M239.00M154.00M238.00M247.00M298.00M81.00M352.00M384.00M347.00M345.00M312.00M371.00M433.00M384.00M423.00M377.00M479.00M559.00M512.00M552.00M595.00M529.00M529.00M552.00M671.00M596.00M599.00M624.00M682.00M-602.00M718.00M721.00M603.00M601.00M691.00M
Diluted EPS 0.380.040.410.450.480.310.480.500.610.160.720.790.710.710.650.770.900.800.880.791.001.171.071.161.261.121.131.191.451.291.311.371.50-1.411.611.631.371.421.65

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 4.23B4.34B4.56B4.79B4.76B4.89B5.31B5.83B6.26B6.67B7.78B8.08B8.54B9.26B9.47B
Cost of Revenue -----------2.45B2.56B2.72B2.67B
Gross Profit -----------5.63B5.98B6.54B6.80B
Operating Expenses -----------2.70B2.91B3.15B3.20B
Operating Income -----------2.93B3.07B3.39B3.60B
EBITDA -----------3.34B3.67B3.85B4.07B
Interest Expense -----------221.00M239.00M225.00M222.00M
Pretax Income -----------2.66B2.94B3.13B3.36B
Tax Provision -----------545.00M596.00M637.00M687.00M
Net Income 245.00M436.00M504.00M583.00M339.00M821.00M864.00M1.43B1.50B1.64B2.04B2.11B2.34B2.49B2.67B
Diluted EPS 0.490.871.011.160.681.651.752.933.113.424.274.495.075.476.02

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --6.26B6.56B6.59B7.91B7.65B8.59B10.78B11.54B13.61B-14.93B14.29B14.24B15.47B
Current Assets ------------7.51B6.34B5.99B6.77B
Cash & Equivalents 63.00M79.00M317.00M610.00M882.00M1.15B727.00M1.56B----3.58B2.04B1.99B2.31B
Inventory ------------2.35B2.56B2.31B2.43B
Receivables ------------1.22B1.30B1.32B1.59B
Total Liabilities --2.22B5.60B5.25B6.82B6.15B6.80B8.59B8.84B9.84B-10.52B9.29B9.47B12.14B
Current Liabilities --1.12B1.42B1.09B1.78B1.12B1.09B1.22B1.81B2.17B-3.17B1.89B3.41B2.23B
Long Term Debt --03.64B3.62B4.46B4.47B4.95B6.44B5.95B6.59B-6.55B6.56B5.22B9.04B
Total Debt ------------8.09B6.75B6.74B9.24B
Total Equity 3.34B3.74B4.03B940.00M1.31B1.07B1.49B1.77B2.19B2.71B3.77B-4.41B5.00B4.77B3.33B
Shares Outstanding ------------501.89M501.89M501.89M501.89M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 497.00M454.00M681.00M626.00M664.00M713.00M1.35B1.79B1.79B2.13B-1.91B2.35B2.95B2.90B
Investing Cash Flow -449.00M-135.00M-179.00M-187.00M-1.11B-214.00M-270.00M-2.26B-504.00M-572.00M--883.00M-777.00M-315.00M-748.00M
Financing Cash Flow -30.00M-78.00M-200.00M-154.00M755.00M-903.00M-251.00M533.00M-951.00M123.00M--904.00M-3.11B-2.66B-1.87B
Capital Expenditure -135.00M-126.00M-184.00M-180.00M-224.00M-216.00M-224.00M-338.00M-460.00M-453.00M--586.00M-732.00M-655.00M-621.00M
Free Cash Flow 362.00M328.00M497.00M446.00M440.00M497.00M1.12B1.45B1.33B1.67B-1.33B1.62B2.30B2.28B
Net Change in Cash -----------125.00M-1.53B-22.00M286.00M
Share Buybacks --00203.00M300.00M500.00M698.00M626.00M250.00M743.00M1.59B1.09B1.86B3.23B

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------69.6%70.0%70.6%71.8%
Operating Margin % -----------36.2%35.9%36.6%38.0%
Net Margin % 5.8%10.1%11.1%12.2%7.1%16.8%16.3%24.5%24.0%24.5%26.2%26.2%27.4%26.9%28.2%
ROE % 6.6%10.8%53.6%44.5%31.7%55.2%48.8%65.4%55.4%43.5%-48.0%46.9%52.1%80.2%
ROCE % -----------24.9%24.8%31.3%27.2%

Shareholding Pattern

Insiders
0.16%
Institutions
100.19%
Public Float
100.35%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.54% 39.43M $3.05B
2 Vanguard Capital Management LLC 6.30% 26.03M $2.01B
3 Vanguard Portfolio Management LLC 5.77% 23.86M $1.85B
4 State Street Corporation 4.76% 19.67M $1.52B
5 State Farm Mutual Automobile Insurance Co 3.85% 15.89M $1.23B
6 Geode Capital Management, LLC 3.22% 13.29M $1.03B
7 Wellington Management Group, LLP 2.28% 9.42M $728.84M
8 Morgan Stanley 2.15% 8.88M $686.69M
9 Nordea Investment Management AB 1.60% 6.59M $509.87M
10 Deutsche Bank AG 1.42% 5.85M $452.57M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ZTS

Yahoo Finance Mon, 07 Sep 2026

Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030

249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With ConfidenceDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Veterinary Diagnosti…

Yahoo Finance hu, 03 Sep 2026

Is Zoetis Stock Underperforming the S&P 500?

Zoetis has significantly lagged the broader market over the past year, while analysts remain cautiously optimistic about its outlook.

Yahoo Finance Wed, 02 Sep 2026

Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

PARSIPPANY, N.J., September 02, 2026--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the M…

Yahoo Finance Mon, 31 Aug 2026

Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared

The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.

Yahoo Finance Mon, 24 Aug 2026

Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?

The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product…

Yahoo Finance Sun, 23 Aug 2026

Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?

Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 bi…

ZTS — Frequently Asked Questions

What is the current share price of Zoetis Inc. (ZTS)?

As of 2026-09-07 16:24 PDT, Zoetis Inc. (ZTS) trades at $75.81 on NYSE. Its 52-week range is $71.36 to $153.81.

What is the market capitalisation of ZTS?

Zoetis Inc. (ZTS) has a market capitalisation of $31.33B on NYSE.

What is the P/E ratio of ZTS?

ZTS trades at a trailing price-to-earnings (P/E) ratio of 12.47. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 9.27.

Does ZTS pay a dividend?

Zoetis Inc. (ZTS) currently offers a dividend yield of 2.74%.

What is the return on equity (ROE) of ZTS?

ZTS has a return on equity (ROE) of 80.25%. Its return on capital employed (ROCE) is 27.18%.

Is ZTS a good stock to buy?

This page provides a data-driven analysis of Zoetis Inc. (ZTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space